Under-recognition of platelet dysfunction in myelodysplastic syndromes: Are we only seeing the tip of the iceberg?

Leukemia and Lymphoma

Volumn 54, Issue 1, 2013, Pages 11-13

  Burbury, Kate L ^a   Seymour, John F ^a,b   Dauer, Ray ^a   Westerman, David A ^a,b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BLEEDING; HUMAN; IMMUNE DYSREGULATION; MYELODYSPLASTIC SYNDROME; NOTE; PHENOTYPE; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOCYTE DYSFUNCTION; THROMBOCYTOPENIA; THROMBOCYTOPOIESIS;

HUMANS; MALE; MYELODYSPLASTIC SYNDROMES;

EID: 84870941516     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.710908     Document Type: Note

References (20)

1. Fenaux P. Myelodysplastic syndromes: From pathogenesis and prognosis to treatment. Semin Hematol 2004 ; 41: 6-12. (Pubitemid 38649813)
2. Kantarjian H, Giles F, List A, et al. The incidence and impact of thrombocytopenia in myelodysplastic syndromes. Cancer 2007 ; 109: 1705-1714. (Pubitemid 46668530)
3. Van Der Meeren S, De Becker A, De Waele M, et al. Symptomatic myelodysplasia with normal blood counts: A diagnostic enigma complicating the management of a patient with severe platelet dysfunction. Leuk Lymphoma 2013; 54: 202- 204.
4. M arisavljevic D, A ntunovic P, M iljic P, et al. P latelet dysfunction as the presenting feature of atypical myelodysplastic syndrome with monosomy 7, normal blood counts and no bleeding tendency. Med Oncol 1998 ; 15: 275-278. (Pubitemid 29049193)
5. Vladareanu AM, Vasilache V, Bumbea H, et al. Platelet dysfunction in acute leukemias and myelodysplastic syndromes. Rom J Intern Med 2011 ; 49: 93-96.
6. Manoharan A, Brighton T, Gemmell R, et al. Platelet dysfunction in myelodysplastic syndromes: A clinicopathological study. Int J Hematol 2002 ; 76: 272-278. (Pubitemid 43020317)
7. Pamphilon DH, Aparicio SR, Roberts BE, et al. The myelodysplastic syndromes - a study of haemostatic function and platelet ultrastructure. Scand J Haematol 1984 ; 33: 486-491. (Pubitemid 15180570)
8. F rö b el J, Hartwig S, A ivado Met al. P roteome analysis of platelets from patients with myelodysplastic syndrome shows low expression of proteins required for GPIIb/IIIa function and platelet aggregation. Leuk Res 2009; 22: 40.
9. Zeidman A, Sokolover N, Fradin Z, et al. Platelet function and its clinical signifi cance in the myelodysplastic syndromes. Hematol J 2004 ; 5: 234-238. (Pubitemid 38931329)
10. Mittelman M, Zeidman A. Platelet function in the myelodysplastic syndromes. Int J Hematol 2000 ; 71: 95-98.
11. Psaila B, Bussel JB, Frelinger AL, et al. Diff erences in platelet function in patients with acute myeloid leukemia and myelodysplasia compared to equally thrombocytopenic patients with immune thrombocytopenia. J Th romb Haemost 2011; 9: 2302- 2310.
12. Michelson AD. Evaluation of platelet function by fl ow cytometry. Pathophysiol Haemost Th romb 2006; 35: 67- 82.
13. Page LK, Psaila B, Provan D, et al. The immune thrombocytopenic purpura (ITP) bleeding score: Assessment of bleeding in patients with ITP. Br J Haematol 2007 ; 138: 245-248. (Pubitemid 46976321)
14. Pellagatti A, Cazzola M, Giagounidis A, et al. Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells. Leukemia 2010; 24: 756-764.
15. Gilli SC, de Souza Medina S, d e Castro V, et al. P latelet associated IgG may be related with thrombocytopenia in patients with myelodysplastic syndromes. Leuk Res 2012; 36: 554- 559.
16. W ang J D, P an X L, Y in Z, et al. E xpression of specifi c antibodies against platelet glycoproteins in patients with mds and its signifi cance. J Exp Hematol/Chinese Association of Pathophysiology 2007 ; 15: 95-98.
17. Kuroda J, Kimura S, Kobayashi Y, et al. Unusual myelodysplastic syndrome with the initial presentation mimicking idiopathic thrombocytopenic purpura. Acta Haematol 2002 ; 108: 139-143. (Pubitemid 35316748)
18. Hayward CP, Moff at KA, Raby A, et al. Development of North American consensus guidelines for medical laboratories that perform and interpret platelet function testing using light transmission aggregometry. Am J Clin Pathol 2010 ; 134: 955-963.
19. Moff at K A, L edford-Kraemer M R, N ichols W L, et al. V ariability in clinical laboratory practice in testing for disorders of platelet function: Results of two surveys of the North American Specialized Coagulation Laboratory Association. Th romb Haemost 2005; 93: 549- 553. (Pubitemid 40392545)
20. S antini V, F enaux P, M ufti G J, et al. M anagement and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine. Eur J Haematol 2010 ; 85: 130-138.